Pharmacokinetic analysis of cefozopran in neonatal infections: Population pharmacokinetics using nonmem

Yuichi Sakurai, Tamotsu Hishikawa, Nobuyoshi Hiramatsu, Yasuhito Sagara, Masaaki Kuwahara, Masaru Nagasaki, Tomoko Hujimaki, Ryochi Fuji

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

This report describes the results on pharmacokinetics, efficacy and safety of cefozopran (CZOP) in neonatal patients. Enrolled patients were 136 in total whose informed consents to enter this study had been given by their parents. Among them, blood samples were collected from 42 neonates to analyze concentrations of CZOP by population pharmacokinetics (PPK) methods. Based on this analysis, the average pharmacokinetic parameters of CZOP and the variabilities of them in different morbid pharmacological backgrounds and in different subjects were evaluated. This PPK analysis showed that clearance (CL) and distribution volume (Vd) of CZOP could be estimated by the following equations; CL=0.0452XWT 1.75 (in the case of the postnatal age of over than 1 day) CL=0.623X0.0452WT 1.765 (in the case of the postnatal age of 1 day or less) Vd = 0.455XWT where WT indicates body weight in kg. The coefficients of variation among individual subjects on CL and Vd were found to he 20.7% and 20.0%, respectively. From this PPK analysis it was indicated that the elimination of CZOP is dependent on the postnatal age and is approximately 38% lower in the younger group than in the older group. Therefore, it could be concluded that, though the cases of evaluation were small in number, adjustment of dosing of CZOP is necessary, particularly in prolongation of intervals of administration, in cases of postnatal age of 1 day or less.

Original languageEnglish
Pages (from-to)16-23
Number of pages8
JournalJapanese Journal of Antibiotics
Volume52
Issue number1
Publication statusPublished - Jan 1999
Externally publishedYes

Fingerprint

Pharmacokinetics
Infection
Population
Social Adjustment
Informed Consent
cefozopran
Parents
Body Weight
Newborn Infant
Pharmacology
Safety

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Sakurai, Y., Hishikawa, T., Hiramatsu, N., Sagara, Y., Kuwahara, M., Nagasaki, M., ... Fuji, R. (1999). Pharmacokinetic analysis of cefozopran in neonatal infections: Population pharmacokinetics using nonmem. Japanese Journal of Antibiotics, 52(1), 16-23.

Pharmacokinetic analysis of cefozopran in neonatal infections : Population pharmacokinetics using nonmem. / Sakurai, Yuichi; Hishikawa, Tamotsu; Hiramatsu, Nobuyoshi; Sagara, Yasuhito; Kuwahara, Masaaki; Nagasaki, Masaru; Hujimaki, Tomoko; Fuji, Ryochi.

In: Japanese Journal of Antibiotics, Vol. 52, No. 1, 01.1999, p. 16-23.

Research output: Contribution to journalArticle

Sakurai, Y, Hishikawa, T, Hiramatsu, N, Sagara, Y, Kuwahara, M, Nagasaki, M, Hujimaki, T & Fuji, R 1999, 'Pharmacokinetic analysis of cefozopran in neonatal infections: Population pharmacokinetics using nonmem', Japanese Journal of Antibiotics, vol. 52, no. 1, pp. 16-23.
Sakurai Y, Hishikawa T, Hiramatsu N, Sagara Y, Kuwahara M, Nagasaki M et al. Pharmacokinetic analysis of cefozopran in neonatal infections: Population pharmacokinetics using nonmem. Japanese Journal of Antibiotics. 1999 Jan;52(1):16-23.
Sakurai, Yuichi ; Hishikawa, Tamotsu ; Hiramatsu, Nobuyoshi ; Sagara, Yasuhito ; Kuwahara, Masaaki ; Nagasaki, Masaru ; Hujimaki, Tomoko ; Fuji, Ryochi. / Pharmacokinetic analysis of cefozopran in neonatal infections : Population pharmacokinetics using nonmem. In: Japanese Journal of Antibiotics. 1999 ; Vol. 52, No. 1. pp. 16-23.
@article{148c365940134948a05bf7035bf86c06,
title = "Pharmacokinetic analysis of cefozopran in neonatal infections: Population pharmacokinetics using nonmem",
abstract = "This report describes the results on pharmacokinetics, efficacy and safety of cefozopran (CZOP) in neonatal patients. Enrolled patients were 136 in total whose informed consents to enter this study had been given by their parents. Among them, blood samples were collected from 42 neonates to analyze concentrations of CZOP by population pharmacokinetics (PPK) methods. Based on this analysis, the average pharmacokinetic parameters of CZOP and the variabilities of them in different morbid pharmacological backgrounds and in different subjects were evaluated. This PPK analysis showed that clearance (CL) and distribution volume (Vd) of CZOP could be estimated by the following equations; CL=0.0452XWT 1.75 (in the case of the postnatal age of over than 1 day) CL=0.623X0.0452WT 1.765 (in the case of the postnatal age of 1 day or less) Vd = 0.455XWT where WT indicates body weight in kg. The coefficients of variation among individual subjects on CL and Vd were found to he 20.7{\%} and 20.0{\%}, respectively. From this PPK analysis it was indicated that the elimination of CZOP is dependent on the postnatal age and is approximately 38{\%} lower in the younger group than in the older group. Therefore, it could be concluded that, though the cases of evaluation were small in number, adjustment of dosing of CZOP is necessary, particularly in prolongation of intervals of administration, in cases of postnatal age of 1 day or less.",
author = "Yuichi Sakurai and Tamotsu Hishikawa and Nobuyoshi Hiramatsu and Yasuhito Sagara and Masaaki Kuwahara and Masaru Nagasaki and Tomoko Hujimaki and Ryochi Fuji",
year = "1999",
month = "1",
language = "English",
volume = "52",
pages = "16--23",
journal = "The Journal of antibiotics. Ser. B",
issn = "0368-2781",
publisher = "Japan Antibiotics Research Association",
number = "1",

}

TY - JOUR

T1 - Pharmacokinetic analysis of cefozopran in neonatal infections

T2 - Population pharmacokinetics using nonmem

AU - Sakurai, Yuichi

AU - Hishikawa, Tamotsu

AU - Hiramatsu, Nobuyoshi

AU - Sagara, Yasuhito

AU - Kuwahara, Masaaki

AU - Nagasaki, Masaru

AU - Hujimaki, Tomoko

AU - Fuji, Ryochi

PY - 1999/1

Y1 - 1999/1

N2 - This report describes the results on pharmacokinetics, efficacy and safety of cefozopran (CZOP) in neonatal patients. Enrolled patients were 136 in total whose informed consents to enter this study had been given by their parents. Among them, blood samples were collected from 42 neonates to analyze concentrations of CZOP by population pharmacokinetics (PPK) methods. Based on this analysis, the average pharmacokinetic parameters of CZOP and the variabilities of them in different morbid pharmacological backgrounds and in different subjects were evaluated. This PPK analysis showed that clearance (CL) and distribution volume (Vd) of CZOP could be estimated by the following equations; CL=0.0452XWT 1.75 (in the case of the postnatal age of over than 1 day) CL=0.623X0.0452WT 1.765 (in the case of the postnatal age of 1 day or less) Vd = 0.455XWT where WT indicates body weight in kg. The coefficients of variation among individual subjects on CL and Vd were found to he 20.7% and 20.0%, respectively. From this PPK analysis it was indicated that the elimination of CZOP is dependent on the postnatal age and is approximately 38% lower in the younger group than in the older group. Therefore, it could be concluded that, though the cases of evaluation were small in number, adjustment of dosing of CZOP is necessary, particularly in prolongation of intervals of administration, in cases of postnatal age of 1 day or less.

AB - This report describes the results on pharmacokinetics, efficacy and safety of cefozopran (CZOP) in neonatal patients. Enrolled patients were 136 in total whose informed consents to enter this study had been given by their parents. Among them, blood samples were collected from 42 neonates to analyze concentrations of CZOP by population pharmacokinetics (PPK) methods. Based on this analysis, the average pharmacokinetic parameters of CZOP and the variabilities of them in different morbid pharmacological backgrounds and in different subjects were evaluated. This PPK analysis showed that clearance (CL) and distribution volume (Vd) of CZOP could be estimated by the following equations; CL=0.0452XWT 1.75 (in the case of the postnatal age of over than 1 day) CL=0.623X0.0452WT 1.765 (in the case of the postnatal age of 1 day or less) Vd = 0.455XWT where WT indicates body weight in kg. The coefficients of variation among individual subjects on CL and Vd were found to he 20.7% and 20.0%, respectively. From this PPK analysis it was indicated that the elimination of CZOP is dependent on the postnatal age and is approximately 38% lower in the younger group than in the older group. Therefore, it could be concluded that, though the cases of evaluation were small in number, adjustment of dosing of CZOP is necessary, particularly in prolongation of intervals of administration, in cases of postnatal age of 1 day or less.

UR - http://www.scopus.com/inward/record.url?scp=0033038977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033038977&partnerID=8YFLogxK

M3 - Article

C2 - 10202684

AN - SCOPUS:0033038977

VL - 52

SP - 16

EP - 23

JO - The Journal of antibiotics. Ser. B

JF - The Journal of antibiotics. Ser. B

SN - 0368-2781

IS - 1

ER -